<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817072</url>
  </required_header>
  <id_info>
    <org_study_id>P/2019/462</org_study_id>
    <nct_id>NCT04817072</nct_id>
  </id_info>
  <brief_title>Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease</brief_title>
  <acronym>EMOTION</acronym>
  <official_title>Evaluation of Mood Disorders Under Biologics (Anti-TNF Alpha) in Chronic Inflammatory Rheumatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations&#xD;
      within the joints spine, hand and foot deformities, low quality of life and psychosocial&#xD;
      status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can&#xD;
      lead to the development of anxiety and depression. Prevalences of anxiety increase in&#xD;
      patients suffering of CIRD, compared with healthy individuals. Another connection has been&#xD;
      identified by the links between depression and systemic inflammation. It is proven that&#xD;
      higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa)&#xD;
      affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION&#xD;
      study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of depressive symptoms</measure>
    <time_frame>1 month after initiation of anti-TNFa therapy</time_frame>
    <description>Score achieved on the validated self-report questionnaire (QIDS SR16) evaluating the severity of depressive symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease activity</measure>
    <time_frame>3 months after initiation of anti-TNFa therapy</time_frame>
    <description>Evaluation with CPDAI for psoriatic arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease activity</measure>
    <time_frame>3 months after initiation of anti-TNFa therapy</time_frame>
    <description>Evaluation with DAS28 for rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease activity</measure>
    <time_frame>3 months after initiation of anti-TNFa therapy</time_frame>
    <description>Evaluation with BASDAI for spondyloarthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease activity</measure>
    <time_frame>3 months after initiation of anti-TNFa therapy</time_frame>
    <description>Evaluation with ASDAS for spondyloarthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Fatigue</measure>
    <time_frame>3 months after initiation of anti-TNFa therapy</time_frame>
    <description>Evaluation with Functional Assessment of Chronic Illness Therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pleasure</measure>
    <time_frame>3 months after initiation of anti-TNFa therapy</time_frame>
    <description>Evaluation with Snaith-Hamilton pleasure scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Rheumatic Diseases</condition>
  <condition>Mood Disorders</condition>
  <arm_group>
    <arm_group_label>Chronic inflammatory rheumatic disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample (20mL) for pro-inflammatory cytokines assay</description>
    <arm_group_label>Chronic inflammatory rheumatic disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥18 ; ≤ 80)&#xD;
&#xD;
          -  Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or&#xD;
             peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis&#xD;
             (AS) according to the New York criteria or psoriatic arthritis (PsA) according to&#xD;
             CASPAR criteria&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
          -  Affiliation to a French social security or receiving such a scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having previously received anti-TNFα treatment&#xD;
&#xD;
          -  Patient with previously diagnosed depressive or psychiatric pathology and / or&#xD;
             receiving anti-depressant treatment&#xD;
&#xD;
          -  Subjects with limited legal capacity.&#xD;
&#xD;
          -  Subjects judged by the investigator to be unlikely to comply with study procedures&#xD;
&#xD;
          -  Subjects with no social security coverage.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Subjects still in the exclusion period of another study, or according to the national&#xD;
             registry of clinical trial participants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Toussirot, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Besançon University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charline Vauchy, PhD</last_name>
    <phone>+333 81 21 88 75</phone>
    <email>cvauchy@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magali Nicolier-Pallandre, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eric Toussirot, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNF alpha inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

